Wyoming Nursing And Rehabilitation Center | |
236 Warrior Way, New Richmond, West Virginia 24867 | |
(304) 294-7586 | |
Name | Wyoming Nursing And Rehabilitation Center |
---|---|
Location | 236 Warrior Way, New Richmond, West Virginia |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 60 |
Occupancy Rate | 66.83% |
Medicare ID (CCN) | 515164 |
Legal Business Name | Wyoming Nursing & Rehabilitation Center Llc |
Ownership Type | For Profit - Individual |
NPI Number | 1043376981 |
Organization Name | WYOMING NURSING & REHABILITATION CENTER LLC |
Address | Route 16 Box 149, New Richmond, WV 24867 |
Phone Number | 304-294-7584 |
News Archive
IASIS Healthcare® LLC today announced financial and operating results for the fiscal fourth quarter and year ended September 30, 2009.
Insmed Incorporated, a biopharmaceutical company, today announced that it has begun screening patients for its U.S. phase 2 clinical trial, Treatment with ARIKACE to Realize Greater Efficacy Trial (TARGET-NTM), of ARIKACE (liposomal amikacin for inhalation) in patients with non-tuberculous mycobacterial (NTM) lung disease.
AstraZeneca and the University of Cambridge today announced three new joint schemes to support more than 80 PhD scholarshipsand eight clinical lectureships over the next five years spanning translational science, basic and clinical research.
Although clinical trials have shown that lung cancer screening using low-dose computed tomography (LDCT) can detect lung cancers early and reduce lung cancer mortality, less than half of family physicians in a recent survey agreed that screening reduces lung cancer–related deaths.
› Verified 7 days ago
NPI Number | 1073227104 |
Organization Name | WARRIOR LEASING CO., LLC |
Address | 236 Warrior Way, New Richmond, WV 24867 |
Phone Number | 304-294-7584 |
News Archive
IASIS Healthcare® LLC today announced financial and operating results for the fiscal fourth quarter and year ended September 30, 2009.
Insmed Incorporated, a biopharmaceutical company, today announced that it has begun screening patients for its U.S. phase 2 clinical trial, Treatment with ARIKACE to Realize Greater Efficacy Trial (TARGET-NTM), of ARIKACE (liposomal amikacin for inhalation) in patients with non-tuberculous mycobacterial (NTM) lung disease.
AstraZeneca and the University of Cambridge today announced three new joint schemes to support more than 80 PhD scholarshipsand eight clinical lectureships over the next five years spanning translational science, basic and clinical research.
Although clinical trials have shown that lung cancer screening using low-dose computed tomography (LDCT) can detect lung cancers early and reduce lung cancer mortality, less than half of family physicians in a recent survey agreed that screening reduces lung cancer–related deaths.
› Verified 7 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
IASIS Healthcare® LLC today announced financial and operating results for the fiscal fourth quarter and year ended September 30, 2009.
Insmed Incorporated, a biopharmaceutical company, today announced that it has begun screening patients for its U.S. phase 2 clinical trial, Treatment with ARIKACE to Realize Greater Efficacy Trial (TARGET-NTM), of ARIKACE (liposomal amikacin for inhalation) in patients with non-tuberculous mycobacterial (NTM) lung disease.
AstraZeneca and the University of Cambridge today announced three new joint schemes to support more than 80 PhD scholarshipsand eight clinical lectureships over the next five years spanning translational science, basic and clinical research.
Although clinical trials have shown that lung cancer screening using low-dose computed tomography (LDCT) can detect lung cancers early and reduce lung cancer mortality, less than half of family physicians in a recent survey agreed that screening reduces lung cancer–related deaths.
› Verified 7 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 0 |
Total Amount of Fines in Dollars | $0 |
Number of Payment Denials | 0 |
Total Number of Penalties | 0 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 22.84 | 14.46 |
Percentage of long-stay residents who lose too much weight | 5.26 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 45.16 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 2.18 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 9.6 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 1.38 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 2.67 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 97.33 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 11.3 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 76.34 | 83.88 |
Percentage of short-stay residents who newly received an antipsychotic medication | 4.76 | 1.79 |
Percentage of long-stay residents whose ability to move independently worsened | 26.79 | 17.09 |
Percentage of long-stay residents who received an antianxiety or hypnotic medication | 36.26 | 19.7 |
Percentage of high risk long-stay residents with pressure ulcers | 15.79 | 7.32 |
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 94.01 | 95.98 |
Percentage of short-stay residents who made improvements in function | 61.94 | 67.99 |
Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 53.13 | 82.93 |
News Archive
IASIS Healthcare® LLC today announced financial and operating results for the fiscal fourth quarter and year ended September 30, 2009.
Insmed Incorporated, a biopharmaceutical company, today announced that it has begun screening patients for its U.S. phase 2 clinical trial, Treatment with ARIKACE to Realize Greater Efficacy Trial (TARGET-NTM), of ARIKACE (liposomal amikacin for inhalation) in patients with non-tuberculous mycobacterial (NTM) lung disease.
AstraZeneca and the University of Cambridge today announced three new joint schemes to support more than 80 PhD scholarshipsand eight clinical lectureships over the next five years spanning translational science, basic and clinical research.
Although clinical trials have shown that lung cancer screening using low-dose computed tomography (LDCT) can detect lung cancers early and reduce lung cancer mortality, less than half of family physicians in a recent survey agreed that screening reduces lung cancer–related deaths.
› Verified 7 days ago
Wyoming Nursing And Rehabilitation Center Location: 236 Warrior Way, New Richmond, West Virginia 24867 Phone: (304) 294-7586 |